An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2

被引：0
|
作者：
Chen, C. [1 ]
Rosario, M. [4 ]
Polhamus, D. [5 ]
Zhang, W. [2 ]
Kisfalvi, K. [3 ]
Feagan, B. [7 ]
Sandborn, W. [6 ,8 ]
Vermeire, S.
D'Haens, G. [9 ]
机构：
[1] Takeda, Quantitat Clin Pharmacol, Global Clin Sci, Cambridge, MA USA
[2] Takeda, Res & Dev, Stat & Quantitat Sci, Cambridge, MA USA
[3] Takeda, Res & Dev, Global Clin Sci, Cambridge, MA USA
[4] Takeda, Clin Pharmacol, Deerfield, IL USA
[5] Metrum Res Grp, Tariffville, CT USA
[6] Univ Calif San Diego, Div Gastroenterol, San Diego, CA 92103 USA
[7] Western Univ, Robarts Clin Trials, London, ON, Canada
[8] Univ Hosp Leuven, Dept Gastroenterol, Leuven, Belgium
[9] Amsterdam Univ Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
133
引用
收藏
页码：117 / 118
页数：2
相关论文
共 50 条
  • [41] Corticosteroid Dose Reduction With Vedolizumab Treatment of Crohn's Disease During the GEMINI 2 Trial
    Loftus, Edward V., Jr.
    Siegel, Corey A.
    Panaccione, Remo
    Sandborn, William J.
    Smyth, Michael Dl
    Green, Alexandra
    Xu, Jing
    Abhyankar, Brihad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S789 - S789
  • [42] APPLICATION OF THE CLINICAL DECISION SUPPORT TOOL TO PREDICT TREATMENT OUTCOMES IN CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB SUBCUTANEOUS FORMULATION
    Dulai, Parambir S.
    Lindner, Dirk
    Agboton, Christian
    Alric, Hadrien
    Bamias, Giorgos
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2023, 164 (06) : S307 - S308
  • [43] EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE TREATMENT FOR MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE CELEST STUDY
    Panes, Julian
    Sandborn, William J.
    Loftus, Edward V.
    Van Assche, Gert A.
    Ghosh, Subrata
    Zhou, Qian
    Goteti, Venkata Sasikiran
    Enejosa, Jeffrey V.
    Pangan, Aileen L.
    Lacerda, Ana P.
    GASTROENTEROLOGY, 2018, 154 (06) : S178 - S179
  • [44] Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn's disease: Results from the CELEST study
    Panes, J.
    Sandborn, W. J.
    Loftus, E. V., Jr.
    Van Assche, G.
    Ghosh, S.
    Zhou, Q.
    Goteti, S.
    Enejosa, J. V.
    Pangan, A. L.
    Lacerda, P.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S238 - S239
  • [45] Application of the clinical decision support tool to predict treatment outcomes in Crohn's Disease patients treated with vedolizumab subcutaneous formulation
    Dulai, P.
    Lindner, D.
    Agboton, C.
    Alric, H.
    Bamias, G.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 490 - 491
  • [46] Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
    Wiken, Thea H.
    Hoivik, Marte L.
    Buer, Lydia
    Warren, David J.
    Bolstad, Nils
    Moum, Bjorn A.
    Anisdahl, Karoline
    Smastuen, Milada C.
    Medhus, Asle W.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, : 863 - 873
  • [47] Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
    Vande Casteele, N.
    Feagan, B. G.
    Vermeire, S.
    Yassine, M.
    Coarse, J.
    Kosutic, G.
    Sandborn, W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 229 - 237
  • [48] Efficacy of vedolizumab for the prevention of postoperative recurrence in Crohn's disease: Data from clinical practice from the ENEIDA registry
    Manosa Ciria, M.
    Hinojosa, E.
    Carbajo, A.
    Castro, J.
    Mancenido, N.
    Calvo, M.
    Nunez Alonso, A.
    Gisbert, J. P.
    Nos, P.
    Guardiola, J.
    Sainz, E.
    Sanchez-Rodriguez, E.
    Canete, F.
    Calafat, M.
    Domenech, E.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S554 - S555
  • [49] Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease
    Suleiman, Ahmed Abbas
    Goebel, Aline
    Bhatnagar, Sumit
    D'Cunha, Ronilda
    Liu, Wei
    Pang, Yinuo
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (04) : 839 - 850
  • [50] Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn's disease
    Suleiman, A.
    Goebel, A.
    Bhatnagar, S.
    D'Cunha, R.
    Liu, W.
    Pang, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I514 - I516
12345